Therapy-related acute myeloid leukemia (t-AML), defined as AML arising from prior
cytotoxic, radiation, or immunosuppressive therapy for an unrelated disease, accounts for …

Myelodysplastic syndromes/myelodysplastic neoplasms (MDS) are associated with variable
clinical presentations and outcomes. The initial response criteria developed by the …

Simple Summary Owing to the 40-year worldwide efforts for improving diagnosis and
therapy for acute myeloid leukemia (AML), the second most common type of leukemia in …

Measurable residual disease (MRD) quantified by multiparameter flow cytometry (MFC) is a
strong and independent prognostic factor in acute myeloid leukemia (AML). However …

In acute myeloid leukemia (AML), measurable residual disease (MRD) before or after
allogeneic hematopoietic cell transplantation (HCT) is an established independent indicator …

Allogeneic stem-cell transplant allows for the delivery of curative graft-versus-leukemia
(GVL) in patients with acute myeloid leukemia/myelodysplasia (AML/MDS). Surveillance of T …

A significant body of literature has been generated related to the detection of measurable
residual disease (MRD) at the time of achieving complete remission (CR) in patients with …

Measurable residual disease (MRD) detected by multiparametric flow cytometry (MFC) is
associated with unfavorable outcome in patients with AML. A simple, broadly applicable …

Multiple studies have demonstrated that patients with acute myeloid leukemia (AML) who
have measurable residual disease (MRD) detected during or after treatment have higher …

Treatment of patients with acute myeloid leukemia (AML) fit to receive intensive treatment
and under 65 years of age consists of one or two cycles of high-dose induction (“3+ 7”) …